Visuelle Vorstellungsfähigkeit, Bewegungsvorstellung und mentales Rotieren bei Morbus Parkinson

2003 ◽  
Vol 14 (2) ◽  
pp. 67-80 ◽  
Author(s):  
O. Hirsch ◽  
W. Lehmann ◽  
M. Corth ◽  
B. Röhrle ◽  
S. Schmidt ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mental Rotation ◽  
Rating Scale ◽  
Morbus Parkinson ◽  
Mental Rotation Test ◽  
Rotation Test ◽  
Disease Rating ◽  
Höheres Alter

Zusammenfassung: In dieser Studie wurden Parkinson-Patienten (n = 54) und eine Kontrollgruppe (n = 54) mit dem Mental Rotation Test (MRT), weiteren Verfahren zur visuellen Informationsverarbeitung und zur Bewegungsvorstellung untersucht. Die Kontrollgruppe weist im MRT signifikant mehr richtige Lösungen auf als die Patienten. Besonders ausgeprägt ist dieser Effekt bei den älteren Probanden. Ferner gibt es einen Geschlechtseffekt zugunsten der Männer. Die Patienten mit niedrigen MRT-Leistungen haben ein höheres Alter und einen höheren Wert in der Unified Parkinson's Disease Rating Scale (UPDRS), einer umfassenden Einschätzungsskala zur Schwere der Parkinson-Symptomatik. Die volle Manifestation der bilateralen Schädigung wirkt sich beim mentalen Rotieren besonders leistungsmindernd aus. Die Selbsteinschätzung zur visuellen Leistungsfähigkeit ist bei den Parkinson-Patienten unabhängig von ihrer tatsächlichen Leistungsfähigkeit. Die Befunde zeigen einen deutlichen Zusammenhang zwischen Schwere der Erkrankung und der Fähigkeit zum mentalen Rotieren. Damit bietet sich die mentale Rotationsleistung als einer von mehreren diagnostischen Indikatoren an. In Pfadanalysen wurde deutlich, dass die Parkinson-Patienten wahrscheinlich keine mentale Rotation durchführen, sondern auf visuelle Ersatzstrategien in Form von Abgleichungsprozessen zurückgreifen. Ein Training im Bereich des räumlichen Visualisierens (mentales Rotieren) wird empfohlen.

Tiefe Hirnstimulation bei fortgeschrittener Parkinson-Erkrankung

2007 ◽  
Vol 26 (04) ◽  
pp. 251-255 ◽  
Author(s):  
S. Franke ◽  
G. Deuschl
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Morbus Parkinson ◽  
Tiefe Hirnstimulation ◽  
Unerwünschte Wirkungen ◽  
Ca 50 ◽  
Disease Rating ◽  
Körperliche Beschwerden ◽  
Disease Questionnaire

ZusammenfassungIm Kompetenznetz Parkinson wurde seit 2001 unter Leitung der Kieler Universitätsklinik die erste multizentrische, randomisierte und kontrollierte Studie zur Wirksamkeit der tiefen Hirnstimulation (STN-Stimulation) bei der Therapie des fortgeschrittenen Morbus Parkinson durchgeführt. Die tiefe Hirnstimulation wurde erstmals mit einer Kontrollgruppe verglichen, die mit einer optimierten medikamentösen Therapie behandelt wurde. Die Lebensqualität, als wichtigster Zielparameter, wurde mit dem Parkinson’s Disease Questionnaire (PDQ-39), die motorischen Symptome über die Unified Parkinson’s Disease Rating Scale (UPDRS) beurteilt.Die Analyse des PDQ-39 Summationswertes ergab bei den stimulierten Patienten eine deutliche Verbesserung der Lebensqualität von 25%, wobei die Subscores Mobilität, Aktivitäten des Alltags, emotionales Wohlergehen, Stigmatisierung sowie körperliche Beschwerden besonders gut auf die Therapie ansprachen. Unter den motorischen Parametern führte die STN-Stimulation zu einer Verringerung der motorischen OFF-Phasen-Symptome um 41% und der Dyskinesien um 54%. Außerdem besserte sich die Beweglichkeit der Patienten im Tagesverlauf, ON-Phasen nahmen von 3,5 auf 8,4 h zu, OFF-Phasen sanken von 6 auf 1,3 h, außerdem nahmen störende Überbewegungen ab. Zudem konnte bei den stimulierten Patienten die Medikamentendosis um ca. 50% vermindert werden. Bei der ausschließlich medikamentös behandelten Kontrollgruppe zeigten sich keine wesentlichen Veränderungen in den genannten Parametern. Schwere unerwünschte Wirkungen waren in der Stimulationsgruppe häufiger. Weniger schwere unerwünschte Wirkungen waren in der Medikationsgruppe häufiger.

scholarly journals Salivary caffeine in Parkinson’s disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Giorgio Leodori ◽  
Maria Ilenia De Bartolo ◽  
Daniele Belvisi ◽  
Alessia Ciogli ◽  
Andrea Fabbrini ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
De Novo ◽  
Oral Intake ◽  
Caffeine Intake ◽  
Motor Complications ◽  
Disease Rating ◽  
Caffeine Metabolism ◽  
Movement Disorder Society

AbstractWe aimed to investigate salivary caffeine content, caffeine absorption and metabolism in Parkinson’s disease (PD) and verify whether salivary caffeine can be used as a biomarker of PD. We enrolled 98 PD patients and 92 healthy subjects. Caffeine and its major metabolite, paraxanthine, were measured in saliva samples collected before and 4 h after the oral intake of caffeine (100 mg). We measured caffeine absorption as the normalized increase in caffeine levels, and caffeine metabolism as the paraxanthine/caffeine ratio. The Movement Disorder Society Unified Parkinson's Disease Rating Scale part III, the Hoehn & Yahr, the presence of motor complications, and levodopa equivalent dose (LED) were assessed and correlated with caffeine levels, absorption, and metabolism. The effects of demographic and environmental features possibly influencing caffeine levels were also investigated. Caffeine levels were decreased in patients with moderate/advanced PD, while caffeine levels were normal in patients with early and de-novo PD, unrelated to caffeine intake. Caffeine absorption and metabolism were normal in PD. Decreased salivary caffeine levels in PD were associated with higher disease severity, longer duration, and the presence of motor complications, no significant association was found with LED. Salivary caffeine decrease correlates with PD progression.

scholarly journals A Comparison of Pain between Parkinson’s Disease and Multiple System Atrophy: A Clinical Cross-Sectional Survey

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
He-Yang You ◽  
Lei Wu ◽  
Hai-Ting Yang ◽  
Chen Yang ◽  
Xiao-Ling Ding
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Rating Scale ◽  
Depression Scale ◽  
Healthy Controls ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Disease Rating ◽  
Vas Scores

Background. Pain is frequent in Parkinson’s disease (PD) and Parkinson-plus syndrome. This study aimed to assess the prevalence, characteristics, therapy (especially the effect of dopaminergic therapy), and associated symptoms of pain in Parkinson's disease and multiple system atrophy (MSA) patients. Methods. Seventy-one PD patients, sixty-five MSA patients, and forty age-matched healthy controls were enrolled and evaluated by using the German pain questionnaire and visual analogue scale (VAS). In addition, the influence of pain in PD patients on anxiety, depression, and the quality of life was assessed with the Hospital Anxiety and Depression Scale (HADS) and Parkinson’s Disease Questionnaire (PDQ-39). Results. Compared to that of the healthy controls, the PD and MSA patients had a significantly higher presence of pain (P<0.01, P<0.01). PD patients had a higher presence of pain than MSA patients (P=0.007). No difference in VAS scores was observed between the PD and MSA patients (P=0.148). A total of 21 PD patients (42.85%) with pain and 13 MSA patients (43.33%) with pain received treatment. A total of 13 PD patients with pain and 6 MSA patients with pain had an improved pain intensity after using dopaminergic medication. The differences in the disease duration, Hoehn and Yahr stages, and scores on the Unified Parkinson’s Disease Rating Scale motor score, HAD-D, HAD-A, and PDQ-39 were significant between the PD patients with and without pain. Conclusion. PD and MSA patients are prone to pain with insufficient treatment. Pain interventions should be provided as soon as possible to improve the patient’s life.

scholarly journals The Parkinson’s Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures

2020 ◽  
Vol 2 (2) ◽  
Author(s):  
Matthias Luz ◽  
Alan Whone ◽  
Niccolò Bassani ◽  
Richard K Wyse ◽  
Glenn T Stebbins ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cell Line ◽  
Glial Cell ◽  
Neurotrophic Factor ◽  
Rating Scale ◽  
Initial Development ◽  
Disease Rating ◽  
Recent Phase ◽  
Data Source

Abstract There is an increasing need for improved endpoints to assess clinical trial effects in Parkinson’s disease. We propose the Parkinson’s Disease Comprehensive Response as a novel weighted composite endpoint integrating changes measured in three established Parkinson’s outcomes, including: OFF state Movement Disorder Society Unified Parkinson’s Disease Rating Scale Motor Examination scores; Motor Experiences of Daily Living scores; and total good-quality ON time per day. The data source for the initial development of the composite described herein was a recent Phase II trial of glial cell line-derived neurotrophic factor. A wide range of clinically derived relative weights was assessed to normalize for differentially scoring base rates with each endpoint component. The Parkinson’s disease comprehensive response, in contrast to examining practically defined OFF state Unified Parkinson’s Disease Rating Scale Motor Examination scores alone, showed stability over 40 weeks in placebo patients, and all 432 analyses in this permutation exercise yielded significant differences in favour of glial cell line-derived neurotrophic factor. The findings were consistent with results obtained employing three different global statistical test methodologies and with patterns of intra-patient change. Based on our detailed analyses, we conclude it worth prospectively evaluating the clinical utility, validity and regulatory feasibility of using clinically supported final Parkinson’s disease comprehensive response formulas (for both the Unified Parkinson’s Disease Rating Scale-based and Movement Disorders Society-Unified Parkinson’s Disease Rating Scale-based versions) in future disease-modifying Parkinson’s trials. Whilst the data source employed in the initial development of this weighted composite score is from a recent Phase II trial of glial cell line-derived neurotrophic factor, we wish to stress that the results are not described to provide post hoc evidence of the efficacy of glial cell line-derived neurotrophic factor but rather are presented to further the debate of how current regulatory approved rating scales may be combined to address some of the recognized limitations of using individual scales in isolation.

scholarly journals The perception of apathy by caregivers of patients with dementia in Parkinson's disease

2016 ◽  
Vol 10 (4) ◽  
pp. 339-343 ◽  
Author(s):  
Carlos Henrique Ferreira Camargo ◽  
Rafael Arthur Serpa ◽  
Thiago Matnei ◽  
Jivago Szpoganicz Sabatini ◽  
Hélio Afonso Ghizoni Teive
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Neuropsychiatric Symptoms ◽  
Parkinson’S Disease Dementia ◽  
Disease Rating

ABSTRACT Background: Apathy is one of the main neuropsychiatric symptoms in patients with Parkinson's disease (PD) and is associated with Parkinson's disease dementia (PDD). Objective: To identify the characteristics of apathy in individuals with PDD according to caregiver perception. Methods: Thirty-nine patients with PD according to MDS criteria for PDD were included. The following scales were used: the Hoehn and Yahr, the Unified Parkinson's Disease Rating Scale III, Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA Cog), the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Apathy Evaluation Scale (AES). Results: A total of 97.4% of the patients showed results consistent with apathy. Analysis of question 14 of the AES revealed no correlation with the total result of all the questions [r=-1293, r²=0.0167, 95%CI (-0.4274 to 0.1940), P=0.2162], however, there was a correlation of responses to the same question with depression data on the MADRS scale [r=-0.5213, r²=0.2718, 95%CI (-0.7186 to -0.2464), P=0.00033]. Conclusion: Apathy is a disorder associated with PDD. However, the scoring scheme of the AES questions can lead to different interpretations of caregiver responses, highlighting limitations of the tool for use in studies of PDD.

scholarly journals Relationship between manual dexterity and the Unified Parkinson’s Disease Rating Scale-Motor Exam

2016 ◽  
Vol 28 (12) ◽  
pp. 3403-3406 ◽  
Author(s):  
Sujin Hwang ◽  
Chiang-Soon Song
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Manual Dexterity ◽  
Disease Rating

scholarly journals Exploring the Effects of Genetic Variants on Clinical Profiles of Parkinson’s Disease Assessed by the Unified Parkinson’s Disease Rating Scale and the Hoehn–Yahr Stage

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0155758 ◽  
Author(s):  
Chen Shi ◽  
Zheng Zheng ◽  
Qi Wang ◽  
Chaodong Wang ◽  
Dabao Zhang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Genetic Variants ◽  
Rating Scale ◽  
Yahr Stage ◽  
Disease Rating ◽  
Clinical Profiles

Exploration of Parkinson’s Disease Symptomatology Subtypes From the Caregiver Perspective: Implications for Caregiver Burden, Depression, and Anxiety

2021 ◽  
pp. 089198872110491
Author(s):  
Sarah K. Lageman ◽  
Emily K. Donovan ◽  
Teresita Villaseñor ◽  
Paul B. Perrin
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Caregiver Burden ◽  
Rating Scale ◽  
Caregiver Support ◽  
Patient Health ◽  
Disease Rating ◽  
Symptom Patterns ◽  
Caregiver Anxiety ◽  
The U.S

Background: While research has demonstrated associations between Parkinson’s disease (PD) severity and caregiver burden and emotional functioning, less is known about the associations between specific PD symptom patterns and caregiver functioning. Objective: The purpose of the current study was to explore symptomatology subtypes in PD from the caregiver perspective in the U.S. and Mexico and to determine whether caregiver burden, depression, or anxiety differed by PD symptomatology subtype. Methods: Two hundred fifty-three caregivers ( M age = 59.9) completed Parts I and II of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), the Zarit Burden Interview, Patient Health Questionnaire-9, and Generalized Anxiety Disorder-7 scales. Results: Cluster analysis using domains from the MDS-UPDRS revealed 5 symptomatology subtypes: pain/motor predominant, low symptoms, severe diffuse symptoms, moderate restricted symptoms with speech/oral predominant, and mood predominant. Caregiver burden was greatest for caregivers of individuals in the severe diffuse symptom and moderate restricted symptoms with speech/oral predominant clusters. High caregiver depression and caregiver anxiety were observed in all clusters other than the low symptoms cluster. There were no site by cluster interactions, suggesting that symptom patterns contribute to caregiver functioning in similar ways in the U.S. and Mexico. Conclusions: This data-driven analysis revealed 5 symptomatology subtypes of PD from caregivers’ perspectives and highlighted the need for treatments and interventions based on predominant PD symptom expression. Importance of caregiver support across various symptomatology expressions, and particularly on specialist treatment for predominant speech/oral difficulties was recommended.

Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale in Two Independent Cohorts with Early Parkinson’s Disease

2021 ◽  
pp. 1-16
Author(s):  
Michael Bartl ◽  
Mohammed Dakna ◽  
Sebastian Schade ◽  
Tamara Wicke ◽  
Elisabeth Lang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Rating Scale ◽  
De Novo ◽  
Longitudinal Change ◽  
Single Center ◽  
Square Roots ◽  
Disease Rating

Background: The MDS-Unified Parkinson’s disease (PD) Rating Scale (MDS-UPDRS) is the most used scale in clinical trials. Little is known about the predictive potential of its single items. Objective: To systematically dissect MDS-UPDRS to predict PD progression. Methods: 574 de novo PD patients and 305 healthy controls were investigated at baseline (BL) in the single-center DeNoPa (6-year follow-up) and multi-center PPMI (8-year follow-up) cohorts. We calculated cumulative link mixed models of single MDS-UPDRS items for odds ratios (OR) for class change within the scale. Models were adjusted for age, sex, time, and levodopa equivalent daily dose. Annual change and progression of the square roots of the MDS-UDPRS subscores and Total Score were estimated by linear mixed modeling. Results: Baseline demographics revealed more common tremor dominant subtype in DeNoPa and postural instability and gait disorders-subtype and multiethnicity in PPMI. Subscore progression estimates were higher in PPMI but showed similar slopes and progression in both cohorts. Increased ORs for faster progression were found from BL subscores I and II (activities of daily living; ADL) most marked for subscore III (rigidity of neck/lower extremities, agility of the legs, gait, hands, and global spontaneity of movements). Tremor items showed low ORs/negative values. Conclusion: Higher scores at baseline for ADL, freezing, and rigidity were predictors of faster deterioration in both cohorts. Precision and predictability of the MDS-UPDRS were higher in the single-center setting, indicating the need for rigorous training and/or video documentation to improve its use in multi-center cohorts, for example, clinical trials.

Sign in / Sign up

Export Citation Format

Share Document